Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. (Q54641441)

2 June 2018

title

Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. (English)

1 reference

2 June 2018

1 reference

1 reference

Kyu-pyo Kim

1

1 reference

2 June 2018

Min-Hee Ryu

2

1 reference

2 June 2018

Changhoon Yoo

3

1 reference

2 June 2018

Baek-Yeol Ryoo

4

1 reference

2 June 2018

Dae Ro Choi

5

1 reference

2 June 2018

Heung Moon Chang

6

1 reference

2 June 2018

Jae-Lyun Lee

7

1 reference

2 June 2018

Mo Youl Beck

8

1 reference

2 June 2018

Tae Won Kim

9

1 reference

2 June 2018

Yoon-Koo Kang

10

1 reference

2 June 2018

publication date

19 October 2010

1 reference

2 June 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

2 June 2018

volume

68

1 reference

2 June 2018

issue

2

1 reference

2 June 2018

page(s)

285-291

1 reference

2 June 2018

https://scigraph.springernature.com/pub.10.1007/s00280-010-1479-6

exact match

0 references

cites work

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1479-6

10.1007/S00280-010-1479-6

21 January 2018

Identifiers

DOI

1 reference

2 June 2018

1 reference

2 June 2018